KUALA LUMPUR, Oct 28 (Bernama) — Allianz Malaysia Berhad (Allianz Malaysia) Group is supporting University Malaya Medical Centre (UMMC) in its ongoing clinical study on individuals who have had COVID-19 and the development of long-term symptoms or Long COVID.
The 31-month-long study, spearheaded by UMMC’s Dato’ Prof. Dr. Adeeba Kamarulzaman, focuses on the assessment of post-acute COVID-19 syndrome (PACS) in COVID patients and will culminate in December 2024.